Thermo Fisher Scientific/$TMO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Ticker
$TMO
Sector
Primary listing
NYSE
Employees
125,000
Headquarters
Website
TMO Metrics
BasicAdvanced
$214B
32.77
$17.32
0.77
$1.68
0.30%
Price and volume
Market cap
$214B
Beta
0.77
52-week high
$610.97
52-week low
$385.46
Average daily volume
2.4M
Dividend rate
$1.68
Financial strength
Current ratio
1.498
Quick ratio
0.837
Long term debt to equity
62.278
Total debt to equity
69.752
Dividend payout ratio (TTM)
9.48%
Interest coverage (TTM)
5.97%
Profitability
EBITDA (TTM)
10,983
Gross margin (TTM)
41.23%
Net profit margin (TTM)
15.02%
Operating margin (TTM)
18.72%
Effective tax rate (TTM)
7.64%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.03%
Return on equity (TTM)
13.12%
Valuation
Price to earnings (TTM)
32.767
Price to revenue (TTM)
4.917
Price to book
4.2
Price to tangible book (TTM)
-14.79
Price to free cash flow (TTM)
35.189
Free cash flow yield (TTM)
2.84%
Free cash flow per share (TTM)
16.124
Dividend yield (TTM)
0.30%
Forward dividend yield
0.30%
Growth
Revenue change (TTM)
3.22%
Earnings per share change (TTM)
8.54%
3-year revenue growth (CAGR)
-0.33%
10-year revenue growth (CAGR)
10.04%
3-year earnings per share growth (CAGR)
-0.89%
10-year earnings per share growth (CAGR)
13.43%
3-year dividend per share growth (CAGR)
13.14%
10-year dividend per share growth (CAGR)
10.84%
What the Analysts think about TMO
Analyst ratings (Buy, Hold, Sell) for Thermo Fisher Scientific stock.
Bulls say / Bears say
Thermo Fisher’s Q2 2025 adjusted EPS was $5.36, beating analyst estimates of $5.22, and revenue climbed 3% to $10.85 billion, supported by strong lab products sales of $6 billion, reflecting solid demand in end markets (Reuters)
In Q1 2025, Thermo Fisher reported adjusted EPS of $5.15 versus the expected $5.10 and revenue of $10.36 billion compared to the anticipated $10.23 billion, as its specialty diagnostics division posted 3.5% growth, demonstrating operational resilience (Reuters)
The $4.1 billion acquisition of Solventum’s purification and filtration unit will broaden Thermo Fisher’s presence in bioprocessing with a $1 billion-revenue business and is forecast to add $0.28 per share to earnings after closing, strengthening its long-term growth platform (Reuters)
Thermo Fisher is considering selling its slower-growing microbiology diagnostics unit for around $4 billion, indicating a potential divestment that could impact the company’s revenue diversification and growth outlook (Reuters)
Thermo Fisher and Roper Technologies agreed to terminate the $925 million acquisition of Gatan Inc after U.K. regulators expressed competition concerns, emphasizing regulatory risks that may hinder future M&A-driven expansion (Reuters)
The purchase of Solventum’s purification and filtration business will reduce adjusted EPS by about $0.06 in the first year, creating near-term earnings pressure even though it is expected to add to profits over the long term (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TMO Financial Performance
Revenues and expenses
TMO Earnings Performance
Company profitability
TMO News
AllArticlesVideos
Thermo Fisher To Acquire Clario Holdings For $8.875 Billion, Expands Digital Pharma Capabilities
Benzinga3 days ago
Thermo Fisher Scientific to acquire Clario in $8.9B cash deal
Proactive Investors4 days ago
Sethi: Thermo Fisher is a world-class compounder you want in your portfolio
CNBC Television4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Thermo Fisher Scientific stock?
Thermo Fisher Scientific (TMO) has a market cap of $214B as of November 02, 2025.
What is the P/E ratio for Thermo Fisher Scientific stock?
The price to earnings (P/E) ratio for Thermo Fisher Scientific (TMO) stock is 32.77 as of November 02, 2025.
Does Thermo Fisher Scientific stock pay dividends?
Yes, the Thermo Fisher Scientific (TMO) stock pays dividends to shareholders. As of November 02, 2025, the dividend rate is $1.68 and the yield is 0.3%. Thermo Fisher Scientific has a payout ratio of 9.48% on a trailing twelve-month basis.
When is the next Thermo Fisher Scientific dividend payment date?
The next Thermo Fisher Scientific (TMO) dividend payment date is unconfirmed.
What is the beta indicator for Thermo Fisher Scientific?
Thermo Fisher Scientific (TMO) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.